This webinar is chaired by Professor Sanjay Popat; The Royal Marsden and welcomes Dr David S. Hong; MD Anderson Cancer Centre. There are four presentations: Larotrectinib in non-CNS patients TRK fusion cancer patients: Outcomes by prior therapy and performance status. Identifying an actionable biomarker a patient case (lung). Treating an actionable biomarker a patient case (sarcoma). The value of testing all patients practicalities for sarcomas. This webinar is initiated and funded by Bayer.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power.
Our products help address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources.
